Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
Eton Pharmaceuticals (Nasdaq: ETON), a company focused on rare disease treatments, announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 27, 2025. This addition marks a significant milestone for the company, reflecting its strong performance and shareholder value creation over the past year.
CEO Sean Brynjelsen highlighted this achievement as an opportunity to increase the company's visibility among investors while continuing their mission of developing treatments for ultra-rare conditions.
Eton Pharmaceuticals (Nasdaq: ETON), un'azienda specializzata in trattamenti per malattie rare, ha annunciato la sua inclusione negli indici Russell 2000® e Russell 3000® a partire dal 27 giugno 2025. Questo traguardo rappresenta un momento importante per la società, testimoniando la sua solida performance e la creazione di valore per gli azionisti nell'ultimo anno.
Il CEO Sean Brynjelsen ha sottolineato che questo risultato offre un'opportunità per aumentare la visibilità dell'azienda tra gli investitori, continuando al contempo la loro missione di sviluppare terapie per condizioni ultra-rare.
Eton Pharmaceuticals (Nasdaq: ETON), una empresa enfocada en tratamientos para enfermedades raras, anunció su inclusión en los índices Russell 2000® y Russell 3000® efectiva a partir del 27 de junio de 2025. Esta incorporación representa un hito importante para la compañía, reflejando su sólido desempeño y la creación de valor para los accionistas durante el último año.
El CEO Sean Brynjelsen destacó este logro como una oportunidad para aumentar la visibilidad de la empresa entre los inversores, mientras continúan con su misión de desarrollar tratamientos para condiciones ultra-raras.
Eton Pharmaceuticals (나스닥: ETON)는 희귀 질환 치료에 집중하는 회사로, 2025년 6월 27일부터 러셀 2000® 및 러셀 3000® 지수에 포함되었음을 발표했습니다. 이번 추가는 회사의 강력한 실적과 지난 1년간 주주가치 창출을 반영하는 중요한 이정표입니다.
CEO 션 브린옐슨은 이번 성과가 투자자들 사이에서 회사의 가시성을 높이고, 초희귀 질환 치료제 개발이라는 미션을 지속할 수 있는 기회라고 강조했습니다.
Eton Pharmaceuticals (Nasdaq : ETON), une entreprise spécialisée dans les traitements des maladies rares, a annoncé son inclusion dans les indices Russell 2000® et Russell 3000® à compter du 27 juin 2025. Cette intégration représente une étape importante pour la société, reflétant sa solide performance et la création de valeur pour les actionnaires au cours de l'année écoulée.
Le PDG Sean Brynjelsen a souligné que cette réussite constitue une opportunité d'accroître la visibilité de l'entreprise auprès des investisseurs tout en poursuivant leur mission de développer des traitements pour des affections ultra-rares.
Eton Pharmaceuticals (Nasdaq: ETON), ein Unternehmen, das sich auf die Behandlung seltener Krankheiten spezialisiert hat, gab seine Aufnahme in die Russell 2000® und Russell 3000® Indizes mit Wirkung zum 27. Juni 2025 bekannt. Diese Aufnahme stellt einen bedeutenden Meilenstein für das Unternehmen dar und spiegelt seine starke Leistung sowie die Wertschaffung für die Aktionäre im vergangenen Jahr wider.
CEO Sean Brynjelsen betonte, dass diese Errungenschaft eine Gelegenheit bietet, die Sichtbarkeit des Unternehmens bei Investoren zu erhöhen und gleichzeitig die Mission fortzusetzen, Behandlungen für ultra-seltene Erkrankungen zu entwickeln.
- Inclusion in Russell 2000® and Russell 3000® Indexes indicates company growth and increased market recognition
- Potential for increased visibility among institutional investors and index funds
- None.
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution.
“Eton’s addition to the Russell 2000 and Russell 3000 Indexes is a significant milestone and recognizes the tremendous shareholder value we’ve generated over the past twelve months. We’re proud to be part of these important market performance benchmarks and look forward to expanding our visibility among investors as we continue bringing much needed treatments to patients with ultra-rare conditions,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. For more information on the Russell 3000® Index and the Russell indexes reconstitution, visit the “Russell Reconstitution” section on the FTSE Russell website.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI®, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
FAQ
When will ETON stock be added to the Russell 2000 and Russell 3000 Indexes?
What does ETON's inclusion in the Russell indexes mean for investors?
Why was Eton Pharmaceuticals added to the Russell indexes?
What is Eton Pharmaceuticals' main business focus?
